Advances in Cancer Immunotherapy: Overcoming the Limitations of Conventional Treatments
ความก้าวหน้าด้านภูมิคุ้มกันบำบัดมะเร็ง: การก้าวข้ามข้อจำกัดในการรักษาแบบเดิม
Keywords:
Immunotherapy, CAR-T cell, Adoptive Cell Therapy, Monoclonal Antibody, Cancer vaccineAbstract
Conventional cancer treatments, such as chemotherapy, radiation therapy, and surgery, present various limitations and challenges, for instance, toxicity of chemotherapy such as myelosuppression and neuropathy, chemotherapy-resistant cancer cells caused treatment failure, and non-specific targeting of cancer cells with radiation therapy or surgery damages to surrounding healthy tissues lead to infection. Cancer immunotherapy has emerged as a promising approach in the field of oncology, offering specific treatment options and less side effect. This approach targets cancer cells directly through various strategies, including immune checkpoint inhibitors, which are monoclonal antibodies that block inhibitory signals on immune responses from cancer, chimeric antigen receptor (CAR) T-cell therapy that T-cells were genetically engineered to express receptors for cancer antigen recognition result in the destruction of cancer cells, and cancer vaccines that stimulate the immune system to recognize cancer-associated antigens. This review provides recent research advancements and the knowledge base on cancer immunotherapy.
Downloads
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74(1):12–49.
Strategy and Planning Division, Ministry of Public Health. Public Health Statistics A.D.2022 [Internet]. Thailand; 2023 [cited 2024 May 20]. Available from: https://spd.moph.go.th/wp-content/uploads/2023/11/Hstatistic65.pdf
กาญจนา อู่สุวรรณทิม. การวิจัยทางภูมิคุ้มกัน (IMMUNOLOGY RESEARCH). พิมพ์ครั้งที่ 1. พิษณุโลก: การพิมพ์ดอทคอม; 2565.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9.
Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med 2015;5(4):a006098.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013 Oct 17;502(7471):333–39.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63.
Carpenter DO, Bushkin-Bedient S. Exposure to chemicals and radiation during childhood and risk for cancer later in life. J Adolesc Health 2013;52(5 Suppl):S21–9.
Bouvard V, Loomis D, Guyton KZ, Grosse Y, Ghissassi FE, Benbrahim-Tallaa L, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol 2015;16(16):1599–600.
McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008;8(3):205–11.
Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006;7(2):149–56.
Kim J, Wang TC. Helicobacter pylori and Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31(3):451–65.
Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al. Mechanisms of Chemotherapy-Induced Neurotoxicity. Front Pharmacol 2022;13:750507.
Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer 2017;17(1):10.
Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36(2):85–94.
Wang X, Rivière I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 2015;22(2):85–94.
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells 2020;9(5):1182.
Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 2018;3(1):e96976.
Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther 2024;31(5):667–86.
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, et al. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov 2023;13(3):580–97.
Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B, et al. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death Dis 2021;12(12):1109.
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127(26):3321–30.
Cohen MD, Keystone E. Rituximab for Rheumatoid Arthritis. Rheumatol Ther 2015;2(2):99–111.
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol 2022;29(5):3044–60.
Pei J, Shu T, Wu C, Li M, Xu M, Jiang M, Zhu C. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program. Front Public Health 2023;10:998174.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411–22.
Kaufman HL, Shalhout SZ, Iodice G. Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Front Mol Biosci 2022;9:834841.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Advanced Science Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
